Patents Assigned to Jazz Pharmaceuticals
-
Patent number: 11986446Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: GrantFiled: December 27, 2021Date of Patent: May 21, 2024Assignee: Jazz Pharmaceuticals Ireland LimitedInventor: Mark Eller
-
Publication number: 20240156759Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: ApplicationFiled: June 30, 2023Publication date: May 16, 2024Applicant: Jazz Pharmaceuticals Ireland LimitedInventors: Clark P. Allphin, Michael DesJardin
-
Patent number: 11980636Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.Type: GrantFiled: November 18, 2021Date of Patent: May 14, 2024Assignee: Jazz Pharmaceuticals Ireland LimitedInventor: Stefan Faderl
-
Patent number: 11858930Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.Type: GrantFiled: July 28, 2021Date of Patent: January 2, 2024Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITEDInventors: Andrew Belfield, Clifford David Jones, Jean-François Margathe, Chiara Colletto
-
Publication number: 20230390228Abstract: Provided herein are methods of treating fibromyalgia, post-traumatic stress disorder, irritable bowel syndrome, and irritable bowel disease in a patient with a slow wave sleep deficit by administering oxybate or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 18, 2021Publication date: December 7, 2023Applicant: Jazz Pharmaceuticals Ireland LimitedInventors: Franck SKOBIERANDA, Mark Toddman KIRBY
-
Patent number: 11802279Abstract: The disclosure provides a modified protein that is a combination of (i) an L-asparaginase and (ii) one or more (poly)peptide(s), wherein the (poly)peptide consists solely of proline and alanine amino acid residues, and methods of preparation and use thereof.Type: GrantFiled: June 1, 2021Date of Patent: October 31, 2023Assignee: Jazz Pharmaceuticals Ireland Ltd.Inventors: Lars Friedrich, Anne O'Donnell
-
Publication number: 20230339910Abstract: Provided herein are compounds identified as inhibitors of KRAS protein activity that can be used to treat various diseases and disorders, such as cancer.Type: ApplicationFiled: January 29, 2021Publication date: October 26, 2023Applicant: Jazz Pharmaceuticals Ireland LimitedInventors: Andrew BELFIELD, Nicolas Emmanuel Stephane GUISOT, Clifford David JONES, Chiara COLLETTO
-
Patent number: 11571440Abstract: The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and/or neurotoxicity.Type: GrantFiled: April 12, 2019Date of Patent: February 7, 2023Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITEDInventors: Sarah McMahon, Yasuhiro Oki
-
Patent number: 11554102Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: GrantFiled: May 12, 2020Date of Patent: January 17, 2023Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITEDInventors: Clark P. Allphin, Michael DesJardin
-
Patent number: 11456081Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients and/or caregivers. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.Type: GrantFiled: July 11, 2018Date of Patent: September 27, 2022Assignee: Jazz Pharmaceuticals, Inc.Inventors: Prasheel Vashdev Lillaney, Sherice Reneé Mills, Gary Joseph Appio
-
Patent number: 11426373Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: GrantFiled: December 22, 2020Date of Patent: August 30, 2022Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Clark P. Allphin, Gunjan Junnarkar, Roman Skowronski, Cuiping Chen, Katayoun Zomorodi, Mark Eller
-
Patent number: 11413264Abstract: The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.Type: GrantFiled: July 31, 2018Date of Patent: August 16, 2022Assignee: Jazz Pharmaceuticals Ireland LimitedInventor: Fionn Hurley
-
Patent number: 11410779Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients and/or caregivers. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.Type: GrantFiled: July 11, 2018Date of Patent: August 9, 2022Assignee: Jazz Pharmaceuticals, Inc.Inventors: Prasheel Vashdev Lillaney, Sherice Reneé Mills, Gary Joseph Appio
-
Patent number: 11400052Abstract: The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping. Provided are formulations that have improved resistance to rapid release of the active ingredient in the presence of increasing amounts of alcohol. Also provided are formulations that can reduce or prevent the release of the active ingredient following exposure to alcohol-containing media. The invention also relates to methods of making the formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: GrantFiled: November 19, 2019Date of Patent: August 2, 2022Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Edwin Walsh, Clark Patrick Allphin
-
Publication number: 20220193015Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: ApplicationFiled: December 27, 2021Publication date: June 23, 2022Applicant: Jazz Pharmaceuticals Ireland LimitedInventor: Mark ELLER
-
Patent number: 11364215Abstract: The present application relates to GHB formulations and methods for manufacturing the same.Type: GrantFiled: April 5, 2021Date of Patent: June 21, 2022Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITEDInventors: Clark Allphin, Scott Bura
-
Patent number: 11253494Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: GrantFiled: March 29, 2021Date of Patent: February 22, 2022Assignee: Jazz Pharmaceuticals Ireland LimitedInventor: Mark Eller
-
Publication number: 20220000815Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: ApplicationFiled: September 20, 2021Publication date: January 6, 2022Applicant: Jazz Pharmaceuticals Ireland LimitedInventors: Clark P. Allphin, Michael DesJardin
-
Patent number: RE49361Abstract: This invention relates to novel compounds. The compounds of the invention are kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Raf kinases, e.g., B-Raf and C-Raf. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Raf kinases, for example, cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia.Type: GrantFiled: November 24, 2020Date of Patent: January 10, 2023Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Matilda Bingham, Richard Testar, Camille Gignoux
-
Patent number: RE49736Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.Type: GrantFiled: March 18, 2020Date of Patent: November 28, 2023Assignee: Jazz Pharmaceuticals II SASInventor: Thierry Abribat